SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer remains under intense scrutiny after a federal indictment revealed that former employees and a co-founder allegedly used shell companies and falsified documents to smuggle controlled technology to China. While the company stated it is cooperating with authorities and was not named as a defendant, investors are heavily debating the potential for long-term reputational damage, the risk of institutional divestment, and whether the business can maintain its AI market share amidst the fallout.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors gear up for the upcoming earnings report, with heated community debate surrounding CEO compensation proposals and persistent speculation about potential large-scale acquisitions. The conversation remains heavily focused on alleged market manipulation and short-interest dynamics, keeping market participants on high alert for volatility as the earnings date approaches.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending due to a sharp, unexpected pullback that has traders debating whether the ETF is experiencing a liquidity-driven liquidation or a fundamental breakdown of its safe-haven status. Investors are actively discussing the impact of rising bond yields and oil price volatility on gold, with community sentiment divided between those aggressively buying the dip as a long-term hedge against national debt and others warning of further technical downside.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is experiencing heightened trading activity as the market reacts to mixed earnings reports and anticipation surrounding the upcoming March 12 investor event. The community is sharply divided, with bulls pointing to the potential of a mid-size vehicle platform to drive long-term growth, while bears remain focused on persistent cash burn, dilution risks, and the company's long path toward profitability.

WeShop Holdings Ltd. engages in providing a shoppable social network. It offers shopping in fashion and accessories, health and beauty, home and DIY, food and drink, travel and holidays, tech and electronics, and other popular categories. It includes a library of shoppable product reviews from a digital online shopping mall on mobile devices. The company was founded by John Garner on September 21, 2012 and is headquartered in Jersey, the United Kingdom.

WeShop Holdings Ltd - Ordinary Shares - Class A

WeShop Holdings Limited

WeShop is drawing intense community attention due to its highly volatile price action following a direct listing, with participants actively debating its potential as a short-squeeze candidate versus concerns over its low-revenue business model. Discussions are heavily focused on the company's unique reward structure that incentivizes users with equity, leading many to monitor the stock for speculative breakout opportunities reminiscent of previous low-float market runners.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing significant selling pressure and heightened volatility as traders weigh concerns over the company's aggressive pivot toward physical AI and chip manufacturing against broader market anxiety regarding geopolitical tensions. Investors remain deeply divided, with many debating the feasibility of the newly announced chip infrastructure while expressing frustration over the stock's recent multi-month decline and the influence of leadership sentiment on its valuation.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is currently facing significant selling pressure as investors react to reports of the company shutting down its Horizon Worlds VR platform, marking a pivot away from its costly metaverse investments toward AI-driven efficiency. While some community members view the stock's recent decline as a buying opportunity, others remain skeptical about the potential return on massive capital expenditures and the impact of rumored workforce reductions.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Markets are exhibiting significant volatility as participants weigh escalating geopolitical tensions in the Middle East against ongoing concerns about stubborn inflation and interest rate trajectories. Investors are closely monitoring potential impacts on energy supplies and global stability, with community discussion highlighting a mix of defensive hedging and debates over the durability of current market valuations.

Harvest Portfolios Group Inc - Harvest Diversified High Income Shares ETF (Class A Units)

Investors are focused on HHIS as a strategic vehicle for generating monthly cash flow through a covered call strategy on high-conviction U.S. equities. The community frequently debates the trade-off between the fund's high income potential and its sensitivity to market volatility, often highlighting it as a core component for long-term income-focused portfolios.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp. is trending as investors digest a strong earnings beat and substantial government contract backlogs while navigating sector-wide volatility. The community remains focused on the company's role as a critical, domestic supplier for defense and high-tech industries, fueled by the strategic necessity of independent supply chains and ongoing geopolitical supply constraints.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Seth Lederman Purchases 15,000 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) CEO Seth Lederman acquired 15,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 18th. The stock was acquired at an average price of $14.89 per share, for a total transaction of $223,350.00. Following...

Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman Acquires 15,000 Shares

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) CEO Seth Lederman acquired 15,000 shares of Tonix Pharmaceuticals stock in a transaction dated Wednesday, March 18th. The shares were purchased at an average price of $14.89 per share, with a total value of $223,350.00. Following...

Noble Financial Has Optimistic Outlook of TNXP Q1 Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Stock analysts at Noble Financial upped their Q1 2026 EPS estimates for shares of Tonix Pharmaceuticals in a research note issued on...

<ul class="summary-bullets"><li>CEO Seth Lederman said early trends show favorable prescriber uptake and repeat utilization.</li><li>Investors are also watching TNX-4800, with the company planning FDA talks on Phase 2/3 development and potential studies beginning in 2027-2028.</li><li>Tonix posted a net loss of $46.9 million in Q4, compared with a net loss of $22.1 million a year ago.</li></ul><p>Shares of Tonix Pharmaceuticals (TNXP) rose over 1% in premarket trading on Friday as investors cheered early prescription traction for its fibromyalgia drug Tonmya and growing interest in its Lyme disease prevention program, despite a wider quarterly loss.</p><p><a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> is headed for its seventh straight week of losses and has declined 0.3% so far this week.</p><h2 class="st-heading-2"><strong>Tonmya Launch Gains Early Prescriber Traction</strong></h2><p>Tonix said Tonmya, approved by the U.S. Food and Drug Administration (FDA) in August 2025 for fibromyalgia in adults, is showing early adoption after its Nov.17, 2025, commercial launch. The therapy is the first new prescription medicine approved for fibromyalgia in more than 15 years.</p><p>Through Feb.27, more than 1,500 healthcare providers had prescribed Tonmya, about 2,500 patients had initiated treatment and cumulative prescriptions reached nearly 4,200, including bridge prescriptions provided through the company’s specialty pharmacy channel.</p><p>“Early prescription trends reflect favorable prescriber uptake and repeat utilization consistent with our internal launch expectations,” CEO Seth Lederman said in a statement. Tonix has established distribution through wholesalers, specialty pharmacies, and patient support programs, including copay assistance and prior authorization services.</p><p>Speaking at the Life Sciences Virtual Investor Forum on Wednesday, Lederman said early anecdotal feedback suggests patients are reporting positive results and that prescribing is occurring across multiple specialties, including rheumatology, primary care, pain management and neurology.</p><h2 class="st-heading-2"><strong>Lyme Disease Prevention Drug In Focus</strong></h2><p>Investors have also been paying attention to TNX-4800, a long-acting monoclonal antibody for the seasonal prevention of Lyme disease, an area with no FDA-approved vaccines or prophylactic treatments currently available.</p><p>Tonix plans to meet with the FDA this year to discuss Phase 2/3 development options, including a field study and a controlled human infection model study. The company expects investigational products to be available in early 2027, with a U.S. field study potentially beginning in 2027 and a human challenge study planned for 2028.</p><h2 class="st-heading-2"><strong>TNXP Q4 Review</strong></h2><p>Tonix reported fourth-quarter (Q4) revenue of about $534 million, significantly up from $2.6 million a year earlier. However, the company posted a net loss of $46.9 million, or $3.98 per share, compared with a net loss of $22.1 million, or $9.77 per share, in the same period a year ago.</p><p>Tonix ended 2025 with $207.6 million in cash and cash equivalents, which will fund operations into the first quarter of 2027.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for TNXP was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/tnxp_ss_png_63ee8c6e92.webp" alt="tnxp ss.png" width="969" height="141"><figcaption>TNXP sentiment and message volume as of March 13 | Source: Stocktwits</figcaption></figure><p>One user&nbsp;<a href="https://stocktwits.com/curiousturtle2000/message/647416946">called</a> Tonix’s latest&nbsp;earnings report “very encouraging.”</p><p><stembedurl>https://stocktwits.com/curiousturtle2000/message/647416946</stembedurl></p><p>Another user&nbsp;<a href="https://stocktwits.com/StockJayC/message/647411678">said</a>, “$20m-$25m cash burn = 2 years continuing at the current burn with no change to operations or factoring revenue increases,” adding that they expect the stock to rise over $60 by June.&nbsp;</p><p><stembedurl>https://stocktwits.com/StockJayC/message/647411678</stembedurl></p><p>TNXP stock has declined 14% so far this year.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TNXP Stock Rises Premarket: Investors Cheer Early Traction For Fibromyalgia Drug Despite Weak Q4 Print

Tonmya launch gained early uptake, with over 1,500 healthcare providers prescribing the drug until Feb.27.

Equity

Tonix Pharmaceuticals (NASDAQ:TNXP) Releases Earnings Results, Misses Estimates By $0.99 EPS

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) released its earnings results on Thursday. The company reported ($4.15) EPS for the quarter, missing the consensus estimate of ($3.16) by...

Tonix Pharmaceuticals (TNXP) Expected to Announce Earnings on Tuesday

Tonix Pharmaceuticals (NASDAQ:TNXP) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 17. (View Earnings Report at...

Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday...

Tonix Pharmaceuticals (NASDAQ:TNXP) Cut to "Sell" at Wall Street Zen

Wall Street Zen downgraded Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

<ul class="summary-bullets"><li>Tonix intends to advance TNX-4800 with the goal of submitting an application to the FDA seeking approval to market it.</li><li>The company licensed TNX-4800 from its developers at UMass Chan Medical School in September.</li><li>There are currently no FDA-approved vaccines or preventive medicines to protect against Lyme disease.</li></ul><p>Tonix Pharmaceuticals Holding Corp. (TNXP) announced on Monday that it intends to meet with the U.S. Food and Drug Administration in 2026 to discuss the development of its experimental drug in the treatment of Lyme disease.</p><p>The company licensed TNX-4800 from its developers at UMass Chan Medical School in September. It is being developed for annual seasonal use, as one subcutaneous administration in the spring to protect against Lyme disease through fall, or the entire tick season in the U.S., without relying on the recipient’s immune system to generate antibodies.</p><h2 class="st-heading-2">What Is Lyme Disease?</h2><p>Lyme disease is a bacterial infection caused by the bacterium Borrelia burgdorferi and spread by infected blacklegged ticks. It causes symptoms such as a bull's-eye rash, fever, fatigue, and headaches, and, if untreated, can spread to joints, heart, and brain.</p><p>There are currently no FDA-approved vaccines or preventive medicines to protect against Lyme disease. According to Tonix, it is the most common vector-borne infection in the United States, and its incidence is climbing each year.</p><h2 class="st-heading-2">Tonix Eyes Advancing The Drug</h2><p>Tonix intends to advance TNX-4800 with the goal of submitting an application to the FDA seeking approval to market it.</p><p>“We believe a controlled human infection model (CHIM)3-5 study using Borrelia-infected ticks that mimics natural infection would be a potential path to demonstrating TNX-4800 efficacy for approval,” <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1606/tonix-pharmaceuticals-announces-program-updates-on-phase">said</a> CEO Seth Lederman. He added that the firm expects to have the investigational product ready for clinical trials by early 2027.</p><h2 class="st-heading-2">Registered Direct Offering</h2><p>Separately, the company also announced the pricing of a $20.0 million registered direct offering on Monday<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1607/tonix-pharmaceuticals-announces-pricing-of-20-0-million"> at about</a> $16.26 per share/warrant. &nbsp;The firm intends to use the net proceeds from the offering to fund the commercialization of its marketed products, the development of its product pipeline, and general working capital and corporate purposes.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around TNXP stayed within the ‘bearish’ territory while message volume stayed at ‘low’ levels.</p><p>A Stocktwits user sounded optimistic about the stock.</p><p><stembedurl>https://www.stocktwits.com/ZenofWealth/message/640294827</stembedurl></p><p><a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> is down 51% this year and by about 55% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nasa-administrator-jared-isaacman-sees-us-return-to-moon-before-trump-presidential-term-expiry/cLeCD4iREDB">NASA Administrator Jared Isaacman Sees US Return To Moon Before Trump’s Presidential Term Expiry</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug

The company also announced the pricing of a $20 million registered direct offering. 

Noble Financial Has Positive Outlook of TNXP FY2025 Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Investment analysts at Noble Financial raised their FY2025 earnings per share estimates for shares of Tonix Pharmaceuticals in a...

$TNXP Q4 &#39;25 Earnings Results &amp; Recap

Tonix Pharmaceuticals Holding Corp. reported net product revenue of $13.1M in 2025, an increase from $10.1M in 2024, with a net loss of $124M in 2025, an improvement from $130M in 2024.

Stocktwits

Tonix Pharmaceuticals Holding Corp

 Q4 '25 Earnings Results & Recap

Tonix Pharmaceuticals Holding Corp. reported net product revenue of $13.1M in 2025, an increase from $10.1M in 2024, with a net loss of $124M in 2025, an improvement from $130M in 2024.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Current Price	$15.00
Prev Close	$15.77
Open	$15.74
Dividend Yield	0.00%
50-Day Moving Average	$15.55
Beta	1.21
Avg. Volume	333,299.34
PE Ratio	-1.05

52-Week High	$69.97
52-Week Low	$13.07
Market Capitalization	$201.08M
EPS (Annual)	-$14.57
Price to Book	0.78
Revenue Per Employee	$92,302.82

TNXP
Tonix Pharmaceuticals Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TNXP News

TNXPTonix Pharmaceuticals Holding Corp